MANNKIND CORP
MANNKIND CORP (MNKD): 12 pipeline candidates · 1 upcoming catalyst · ~92 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
92.3 months
D/E -13.58 · 0% dilution
Lead: Approved
12 candidates
1 upcoming, next in ~561d
1 buy · 3 sells (180d)
A transparent, data-derived signal for MANNKIND CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1B
Cash
$52.8M
Quarterly Burn
$5.4M
Runway
92.3 mo
Revenue
$90.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| acetazolamide | Approved |
| afrezza | Phase 3 |
| basal insulin | Phase 2 |
| clofazimine inhalation | Phase 3 |
| insulin degludec | Phase 4 |
| lidocaine | Approved |
| mnkd-101 | Phase 3 |
| mnkd-201 | Phase 1 |
| rapid-acting insulin analog | Phase 3 |
| technosphere insulin | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
251
Total value held
$446.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 28,600,998 | $70.1M |
| vanguard capital management llc | 25,782,132 | $63.2M |
| state street corp | 18,683,483 | $45.8M |
| geode capital management, llc | 7,505,147 | $18.4M |
| millennium management llc | 6,390,922 | $15.7M |
| morgan stanley | 5,793,147 | $14.2M |
| dimensional fund advisors lp | 4,953,295 | $12.1M |
| 180 wealth advisors, llc | 4,291,703 | $10.5M |
| rubric capital management lp | 3,620,413 | $8.9M |
| fmr llc | 3,480,964 | $8.5M |
Showing top 10 of 251 institutional holders of MANNKIND CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MANNKIND CORP's pipeline?
MANNKIND CORP (MNKD) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MANNKIND CORP's lead drug candidate?
MANNKIND CORP's most advanced tracked candidate is acetazolamide (Approved) for INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attem.
What is MANNKIND CORP's next catalyst?
MANNKIND CORP's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: afrezza" — expected December 31, 2027.
What is MANNKIND CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MANNKIND CORP has approximately 92.3 months of cash runway.
What is MANNKIND CORP's market capitalization?
MANNKIND CORP's market capitalization is approximately $1.1B.
Get the full picture on MANNKIND CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.